Eli Lilly and Company

Eli Lilly Company

Vincent Patrick Rocco

James E Audia

John M Schaus

Joseph H Krushinski, Jr

Dennis C Thompson

Daniel James Koch

Patrick Gianpietro Spinazze

Jeffrey S Nissen

John Xiaoqiang He

Kurt Rasmussen

Thomas Edward Mabry

David T Wong

Kumiko Takeuchi

Todd Jonathan Kohn

Nicholas Allan Honigschmidt

David J Hibschman

Daniel Jon Sall

Jolie Anne Bastian

Cynthia Darshini Jesudason

Theo Schotten

Don Richard Finley

Andrew Michael Ratz

Freddie Craig Stevens

John Arnold Werner

Blake L Neubauer

Loretta A McQuaid

William George Trankle

Gerd Reuhter

Thomas Daniel Aicher

David Edward Tupper

James Joseph Droste

Bruce Anthony Dressman

Yao-Chang Xu

Stephen W Kaldor

James E Fritz

Zhaogen Chen

Marta Maria Pineiro-Nunez

Kevin Michael Ruley

Sandra Ann Filla

Margaret Mary Faul

Yvan Le Huerou

Marvin M Hansen

Brian Michael Mathes

Thomas J Kress

Ying Chen

Lee A Phebus

Rushad Eruch Karanjawala

James P Wepsiec

Britta Evers

Fionna Mitchell Martin

Kevin L Haehl

Tammy Joy Sajdyk

Yvan LeHuerou

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C) alkylene or hydroxy substituted (C) alkylene; X is oxygen or sulfur; Ris hydrogen, (C) fluroalkyl, (C) cycloalkyl, or (C) alkyl, wherein the (C) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCHCHOH, or &#x2014;CN; Ris H, halogen, (C) fluoroalkyl, (C) cycloalkyl, OR, SR, NO, CN, COR, C(O)OR, CONRR, NRR, SONRR, NRCOR, NRSOR, optionally substituted aromatic, or (C) alkyl, wherein (C) alkyl is unsubstituted or substituted with a hydroxy group; Ris hydrogen (C) fluoroalkyl, (C) alkenyl, Ar, (C)alkyl-Ar, or (C) alkyl wherein (C) alkyly is unsubstituted or substituted with a phenyl; Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic, Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Zand Zare independently selected from hydrogen, halogen, (C) alkyl, (C) fluoroalkyl, OR, SR, NO, CN, COR, CONRR, NRR, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I) 

Piperazine substituted aryl benzodiazepines

Described herein are antipyschotic compounds of formula (I) wherein,

Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity 

&#x3b2;3 adrenergic agonists

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 

Indole derivatives for the treatment of depression and anxiety

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;3 agonists

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;-3 agonists

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine

Benzofuran derivatives

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Tropane linked benzofuran derivatives

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Piperidines derivatives and their use as serotonin receptor antagonists

A class of novel substituted-aryloxy-2-ol-3-(4-spiro-(alkanedioxy)isobenzofuranyl- and phthaloyl-piperidine) derivatives is disclosed useful as 5-HT and 5-HT antagonists.

5-HT1A and 5-HT1D&agr;dalpha antagonists

The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT receptors and inhibiting protein extravasation in a mammal.

5-HT1F agonists

This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.

Inhibitors of serotonin reuptake

This invention provides 5-HT,antagonists of Formula I:

5-HT1F antagonists

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1,receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

Compounds having effects on serotonin-related systems

A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.

5.alpha.-reductase inhibitors

Growing community of inventors

Indianapolis, IN, United States of America

Vincent Patrick Rocco